Sacituzumab govitecan (SG) is an antineoplastic agent, which combines sacituzumab, a humanized monoclonal antibody binding to trophoblast cell-surface antigen-2 (Trop-2)-expressing cancer cells, linked with govitecan (SN38), a topoisomerase I inhibitor. This evidence concerns the gene TACSTD2 and cancer.